D. Fabbro

发表

NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors

Lukasz Skóra, J. Mestan, D. Fabbro, 2013, Proceedings of the National Academy of Sciences.

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

D. Fabbro, M. Warmuth, M. Hallek, 2004, Nature Genetics.

The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation.

D. Fabbro, W. Jahnke, T. Meyer, 2005, Structure.

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology

Adam J Pawson, Stephen P. H. Alexander, C. Southan, 2020, Immunology.

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

Bhabatosh Chaudhuri, Doriano Fabbro, Pascal Furet, 2002, Pharmacology & therapeutics.

Ten things you should know about protein kinases: IUPHAR Review 14

Doriano Fabbro, D. Fabbro, S. Cowan-Jacob, 2015, British journal of pharmacology.

Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4.

D. Fabbro, P. Furet, T. O'reilly, 2001, Journal of the National Cancer Institute.

Antisense oligonucleotides and their anticancer activities

D. Fabbro, M. Müller, T. Geiger, 1998 .

Targeting protein kinases in cancer therapy: a success?

D. Fabbro, M. Pearson, 2004, Expert review of anticancer therapy.

Advances in kinase targeting: current clinical use and clinical trials.

D. Fabbro, M. Rask-Andersen, H. Schiöth, 2014, Trends in pharmacological sciences.

Allosteric inhibitors of Bcr-abl–dependent cell proliferation

J. Mestan, D. Fabbro, N. Gray, 2006, Nature chemical biology.

Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay.

J. Mestan, D. Fabbro, W. Jahnke, 2010, Journal of the American Chemical Society.

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.

F. Lombardo, D. Fabbro, W. Jahnke, 2018, Journal of medicinal chemistry.

Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking.

D. Fabbro, P. Furet, R. Portmann, 2003, Journal of medicinal chemistry.

Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.

D. Fabbro, W. Pickl, F. Lee, 2006 .

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

W. Sellers, D. Fabbro, Christopher J. Wilson, 2011, Molecular Cancer Therapeutics.

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Catalytic receptors

Stephen P. H. Alexander, C. Southan, D. Fabbro, 2021, British journal of pharmacology.

Cancer Biology and the Principles of Targeted Cancer Drug Discovery

J. Mestan, D. Fabbro, D. Schmitz, 2017 .

Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412.

D. Fabbro, S. Rocha, M. Pruschy, 2001, Cancer research.

PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.

D. Fabbro, J. Kutok, J. Fletcher, 2004, Proceedings of the National Academy of Sciences of the United States of America.

In-vitro antiproliferative activities and kinase inhibitory potencies of meridianin derivatives

D. Fabbro, M. Prudhomme, E. Débiton, 2008, Anti-cancer drugs.

Imatinib: a selective tyrosine kinase inhibitor.

D. Fabbro, P. Furet, T. Meyer, 2002, European journal of cancer.

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy

D. Fabbro, L. Cascione, D. Rossi, 2017, Clinical Cancer Research.

Book Review: Protein Tyrosine Kinases. from Inhibitors to Useful Drugs

Frank McCormick, D. Fabbro, F. McCormick, 2006 .

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Daniela Gabriel, Doriano Fabbro, Pascal Furet, 2008, Molecular Cancer Therapeutics.

The Concise Guide to PHARMACOLOGY 2015/16: Enzymes

Christopher Southan, Stephen PH Alexander, Eamonn Kelly, 2015, British journal of pharmacology.

The Concise Guide to Pharmacology 2013/14: Overview

Adam J Pawson, Stephen P. H. Alexander, A. A. Khan, 2013, British journal of pharmacology.

an Inhibitor of Protein Kinase C Target for the Anticancer and Radiosensitizing Agent PKC 412 ,-Kinase / Akt Survival Pathway Is a ′ The Phosphatidylinositide 3 Updated

D. Fabbro, S. Rocha, B. Hemmings, 2001 .

The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C.

D. Fabbro, S. Rocha, B. Hemmings, 2001, Cancer research.

Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC alpha.

D. Fabbro, W. Wetsel, Y. Hannun, 1993, The Journal of biological chemistry.

Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent.

J. Mestan, D. Fabbro, T. Meyer, 1999, Pharmacology & therapeutics.

PREDICTIVE VALUE OF EGF RECEPTOR IN BREAST CANCER

D. Fabbro, U. Eppenberger, H. Stamm, 1988, The Lancet.

Phosphorylation Specificities of Protein Kinase C Isozymes for Bovine Cardiac Troponin I and Troponin T and Sites within These Proteins and Regulation of Myofilament Properties*

D. Fabbro, Y. Hannun, G. Blobe, 1996, The Journal of Biological Chemistry.

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes

Adam J Pawson, Stephen P. H. Alexander, C. Southan, 2017, British journal of pharmacology.

PKC zeta is a molecular switch in signal transduction of TNF‐alpha, bifunctionally regulated by ceramide and arachidonic acid.

D. Fabbro, G. Müller, P. Storz, 1995, The EMBO journal.

A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C.

D. Fabbro, Dylan T. Jones, K. Ganeshaguru, 2002, The hematology journal : the official journal of the European Haematology Association.

Inhibition of Cell Growth by Antisense Oligonucleotides Targeting the Growth-Related Protein Kinase c-raf.

D. Fabbro, K. Altmann, B. Monia, 2000, Methods in molecular medicine.

Expression of four protein kinase C isoforms in rat fibroblasts. Differential alterations in ras-, src-, and fos-transformed cells.

C. Borner, D. Fabbro, I. Weinstein, 1992, The Journal of biological chemistry.

Selective redistribution of protein kinase C isozymes by thapsigargin and staurosporine.

D. Fabbro, P. Parker, S. Kiley, 1992, Carcinogenesis.

Second Generation of Antisense Oligonucleotides: From Nuclease Resistance to Biological Efficacy in Animals

S. Freier, D. Fabbro, F. Natt, 1996, CHIMIA.

Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors.

D. Fabbro, K. Altmann, B. Monia, 1996, Biochemical Society transactions.

Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence.

D. Fabbro, R. Stahel, K. Altmann, 1997, Journal of the National Cancer Institute.

Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor.

D. Fabbro, W. Jahnke, G. Rummel, 2015, ACS medicinal chemistry letters.

PKC412--a protein kinase inhibitor with a broad therapeutic potential.

P. Campochiaro, D. Fabbro, T. Meyer, 2000, Anti-cancer drug design.

Inhibition of mutant FLT 3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC 412

D. Fabbro, T. Meyer, J. Griffin, 2002 .

Medullary Thyroid Cancer Cells inCalcitonin Gene Expression through Distinct Mechanisms The RET Kinase Inhibitor NVP-AST 487 Blocks Growth and Updated

D. Fabbro, H. Lane, M. Santoro, 2007 .

Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth

D. Fabbro, O. Riesterer, M. Pruschy, 2001, British Journal of Cancer.

Advances in Brief Prediction of Resistance to Small Molecule FLT 3 Inhibitors : Implications for Molecularly Targeted Therapy of Acute Leukemia

D. Fabbro, P. Marynen, P. Furet, 2004 .

Regulation of ribosomal protein S6 kinase in human mammary tumor cells: Effect of estrogen, growth factors and phorbol ester

D. Fabbro, U. Eppenberger, A. Matter, 1988, Experientia.

Syntheses, biochemical and biological evaluation of staurosporine analogues from the microbial metabolite rebeccamycin.

D. Fabbro, C. Bailly, M. Sancelme, 1998, Bioorganic & medicinal chemistry.

Staurosporine stimulates expression of the urokinase‐type (u‐PA) plasminogen activator in LLC‐PK1 cells

D. Fabbro, Y. Nagamine, B. Hemmings, 1989, International journal of cancer.

Calcium transients in human platelets monitored by aequorin, fura-2 and quin-2: effects of protein kinase C activation and inhibition.

D. Fabbro, P. Sever, P. Erne, 1987, Biochemical and biophysical research communications.

Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro.

D. Fabbro, M. Šuša, A. Teti, 2003, European journal of cancer.

Kinase inhibition by deoxy analogues of the resorcylic lactone L-783277.

D. Fabbro, K. Altmann, P. Drueckes, 2011, ACS medicinal chemistry letters.

Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice.

D. Fabbro, N. Dean, T. Geiger, 1998, Anti-cancer drug design.

The 27,000 daltons stress proteins are phosphorylated by protein kinase C during the tumor promoter-mediated growth inhibition of human mammary carcinoma cells.

D. Fabbro, U. Eppenberger, R. Regazzi, 1988, Biochemical and biophysical research communications.

Patupilone Acts as Radiosensitizing Agent in Multidrug-Resistant Cancer Cells In vitro and In vivo

D. Fabbro, G. Folkers, M. Pruschy, 2005, Clinical Cancer Research.

IL‐8‐mediated angiogenic responses of endothelial cells to lipid antigen activation of iNKT cells depend on EGFR transactivation

D. Fabbro, P. Erne, M. Philippova, 2011, Journal of leukocyte biology.

Ceramide induces translocation of protein kinase C-alpha to the Golgi compartment of human embryonic kidney cells by interacting with the C2 domain.

D. Fabbro, J. Pfeilschifter, A. Huwiler, 2003, Biochimica et biophysica acta.

Nitric Oxide Induces Degradation of the Neutral Ceramidase in Rat Renal Mesangial Cells and Is Counterregulated by Protein Kinase C*

D. Fabbro, J. Pfeilschifter, A. Huwiler, 2002, The Journal of Biological Chemistry.

Selective ceramide binding to protein kinase C-alpha and -delta isoenzymes in renal mesangial cells.

D. Fabbro, J. Pfeilschifter, A. Huwiler, 1998, Biochemistry.

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.

J. Mestan, D. Fabbro, P. Furet, 2004, Mini reviews in medicinal chemistry.

Effect of tumour-promoting phorbol ester, thrombin and vasopressin on translocation of three distinct protein kinase C isoforms in human platelets and regulation by calcium.

D. Fabbro, P. Erne, S. Stabel, 1992, The Biochemical journal.

Cell Line Synergistically Reduce the Interleukin 3 Requirement in a Mast ras Tumor-promoting Phorbol Ester and Activated Ha-Updated

D. Fabbro, R. Imber, 2006 .

Tumor-promoting phorbol ester and activated Ha-ras synergistically reduce the interleukin 3 requirement in a mast cell line.

D. Fabbro, R. Imber, 1991, Cancer research.

The epsilon isoform of protein kinase C is an oncogene when overexpressed in rat fibroblasts.

D. Fabbro, A. Cacace, I. Weinstein, 1993, Oncogene.

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and Other Protein Targets

Stephen P. H. Alexander, C. Southan, D. Fabbro, 2021, British journal of pharmacology.

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.

D. Fabbro, S. Derdak, W. Pickl, 2006, Blood.

PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases

D. Fabbro, Petra Hillmann, 2019, International journal of molecular sciences.

The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax

D. Fabbro, L. Cascione, A. Stathis, 2019, Cancers.

Platelet-derived growth factor and angiotensin II stimulate the mitogen-activated protein kinase cascade in renal mesangial cells: comparison of hypertrophic and hyperplastic agonists.

D. Fabbro, J. Pfeilschifter, A. Huwiler, 1995, The Biochemical journal.

Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.

D. Fabbro, B. Monia, M. Müller, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Overexpression of the alpha-type protein kinase (PK) C in LLC-PK1 cells does not lead to a proportional increase in the induction of two 12-O-tetradecanoylphorbol-13-acetate-inducible genes.

D. Fabbro, Y. Nagamine, P. Parker, 1991, Cell regulation.

Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.

D. Fabbro, J. Griffin, A. Kung, 2007, Blood.

BCR-ABL signaling: A new STATus in CML.

D. Fabbro, 2012, Nature chemical biology.

Immunocharacterization of δ‐ and ζ‐isoenzymes of protein kinase C in rat renal mesangial cells

D. Fabbro, J. Pfeilschifter, A. Huwiler, 1992 .

Differential recovery of protein kinase C-α and -ɛ isozymes after long-term phorbol ester treatment in rat renal mesangial cells

D. Fabbro, J. Pfeilschifter, A. Huwiler, 1991 .

Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex

D. Fabbro, W. Löscher, S. Roberds, 2020, Neuropharmacology.

Epidermal growth factor binding and protein kinase C activities in human breast cancer cell lines: possible quantitative relationship.

D. Fabbro, U. Eppenberger, R. Regazzi, 1986, Cancer research.

Effects of tumor promoters on growth and on cellular redistribution of phospholipid/CA2+‐dependent protein kinase in human breast cancer cells

C. Borner, D. Fabbro, S. Costa, 1986, International journal of cancer.

Protein kinase C inhibitor and irradiation-induced apoptosis: relevance of the cytochrome c-mediated caspase-9 death pathway.

D. Fabbro, S. Lowe, M. Soengas, 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Protein Kinase C Inhibitor and Irradiation-induced Apoptosis : Relevance of the Cytochrome c-mediated Caspase-9 Death Pathway 1

D. Fabbro, S. Lowe, M. Soengas, 2000 .

The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug.

D. Fabbro, N. Gray, S. Cowan-Jacob, 2022, Journal of medicinal chemistry.

Continuous synthesis of two protein-kinase-C-related proteins after down-regulation by phorbol esters.

C. Borner, D. Fabbro, U. Eppenberger, 1988, Proceedings of the National Academy of Sciences of the United States of America.

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors

Christopher Southan, John A Peters, Elena Faccenda, 2019, British journal of pharmacology.

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes

Christopher Southan, John A Peters, Elena Faccenda, 2019, British journal of pharmacology.

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview

Arthur Christopoulos, Christopher Southan, Stephen PH Alexander, 2017, British journal of pharmacology.

The ceramide kinase inhibitor NVP‐231 inhibits breast and lung cancer cell proliferation by inducing M phase arrest and subsequent cell death

D. Fabbro, J. Pfeilschifter, S. Schwalm, 2014, British journal of pharmacology.

Biosynthesis and posttranslational modifications of protein kinase C in human breast cancer cells.

C. Borner, D. Fabbro, U. Eppenberger, 1989, The Journal of biological chemistry.

Translocation of protein kinase C is not required to inhibit the antigen-induced increase of cytosolic calcium in a mast cell line.

C. Borner, D. Fabbro, P. Erne, 1987, Biochemical and biophysical research communications.

The lipophilic muramyltripeptide MTP-PE, a biological response modifier, is an activator of protein kinase C.

D. Fabbro, T. Meyer, U. Eppenberger, 1986, Biochemical and biophysical research communications.

The cytosolic phorboid receptor correlates with hormone dependency in six mammary carcinoma cell lines.

D. Fabbro, S. Costa, U. Eppenberger, 1985, Biochemical and biophysical research communications.

Subcellular distribution of protein kinase C of GH3 cells: quantitation and characterization by polyacrylamide gel electrophoresis.

D. Fabbro, U. Eppenberger, R. Jungmann, 1985, Archives of biochemistry and biophysics.

Antisense oligonucleotide inhibitors of isozymes of protein kinase C: in vitro and in vivo activity, and clinical development as anti-cancer therapeutics.

L. Miraglia, D. Fabbro, N. Dean, 1997, Anti-cancer drug design.

cAMP-dependent protein kinases, their subunits, and cAMP-binding protein from four sources: a comparison of physical characteristics determined by polyacrylamide gel electrophoresis.

D. Fabbro, U. Eppenberger, A. Chrambach, 1981, Archives of biochemistry and biophysics.

International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands

J. Changeux, R. Neubig, C. Langmead, 2014, Pharmacological Reviews.

Cyclic AMP-dependent protein kinases in semen from men with subnormal sperm motility or morphology

D. Fabbro, A. Campana, U. Eppenberger, 1983 .

Ontogeny of the adenosine-3':5'-phosphate-dependent protein-kinase system during early uterine development. Inverse relationship with the estrogen receptors.

D. Fabbro, J. Weber, U. Eppenberger, 1979, European journal of biochemistry.

Platelet-derived growth factor stimulates de-novo synthesis of mitogen-activated protein kinase in renal mesangial cells.

D. Fabbro, J. Pfeilschifter, A. Huwiler, 1995, European journal of biochemistry.

Hormone- and phorbol ester-activated protein kinase C isozymes mediate a reorganization of the actin cytoskeleton associated with prolactin secretion in GH4C1 cells.

D. Fabbro, P. Parker, S. Kiley, 1992, Molecular endocrinology.

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets

Arthur Christopoulos, Adam J. Pawson, Michael Spedding, 2019, British Journal of Pharmacology.

Inhibition of Growth of Human Tumor Cell Lines in Nude Mice by an Antisense Oligonucleotide Inhibitor of Protein Kinase C-α Expression

L. Miraglia, D. Fabbro, J. Giddings, 1996 .

FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies

Sandra A. Moore, D. Fabbro, J. Kutok, 2005, Oncogene.

Specific CLK Inhibitors from a Novel Chemotype for Regulation of Alternative Splicing

Damian Szklarczyk, Doriano Fabbro, Stefan Knapp, 2011, Chemistry & biology.

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes

Stephen P. H. Alexander, C. Southan, D. Fabbro, 2021, British journal of pharmacology.

Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo.

E. Lesnik, S. Freier, D. Fabbro, 1996, Proceedings of the National Academy of Sciences of the United States of America.

The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy

D. Fabbro, W. Löscher, M. Wymann, 2018, Neuropharmacology.

7,8-Dichloro-1-oxo-β-carbolines as a Versatile Scaffold for the Development of Potent and Selective Kinase Inhibitors with Unusual Binding Modes

Doriano Fabbro, Stefan Knapp, Jörg Trappe, 2011, Journal of medicinal chemistry.

Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties.

D. Fabbro, M. Sancelme, T. Meyer, 1996, Journal of medicinal chemistry.

Synthesis and biological evaluation of diversely substituted indolin-2-ones.

D. Fabbro, M. Sancelme, M. Prudhomme, 2008, European journal of medicinal chemistry.

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.

Doriano Fabbro, Pascal Furet, Giorgio Caravatti, 2013, Bioorganic & medicinal chemistry letters.

25 Years of Small Molecular Weight Kinase Inhibitors: Potentials and Limitations

D. Fabbro, 2015, Molecular Pharmacology.

Synthesis and target identification of hymenialdisine analogs.

L. Meijer, D. Fabbro, N. Gray, 2004, Chemistry & biology.

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.

D. Fabbro, G. Martiny-Baron, J. Brueggen, 2004, Cancer cell.

Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention

D. Fabbro, M. Zvelebil, Roger L. Williams, 2017, Nature Communications.

In-vitro antiproliferative activities and kinase inhibitory potencies of glycosyl-isoindigo derivatives

D. Fabbro, M. Prudhomme, P. Moreau, 2007, Anti-cancer drugs.

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.

J. Mestan, D. Fabbro, M. Zvelebil, 2017, Journal of medicinal chemistry.

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

Doriano Fabbro, Paul Manley, D. Fabbro, 2002, Cancer cell.

Comparison of different tumour promoters and bryostatin 1 on protein kinase C activation and down-regulation in rat renal mesangial cells.

D. Fabbro, J. Pfeilschifter, A. Huwiler, 1994, Biochemical pharmacology.

Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2.

D. Fabbro, P. Furet, T. Meyer, 1995, European journal of biochemistry.

Cyclic adenosine monophosphate-dependent protein kinases of human seminal plasma: origin and characteristics of multiple forms.

D. Fabbro, A. Campana, U. Eppenberger, 1982, Biology of reproduction.

New sesquiterpene quinols from a Micronesian sponge, Aka sp.

D. Fabbro, R. Edrada, F. Schmitz, 2003, Journal of natural products.

A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-Pyrrolo-Oxazine mTOR Inhibitor.

D. Fabbro, M. Wymann, F. Beaufils, 2019, Journal of medicinal chemistry.

Extended kinase profile and properties of the protein kinase inhibitor nilotinib.

J. Mestan, D. Fabbro, G. Martiny-Baron, 2010, Biochimica et biophysica acta.

Protein kinase C desensitization by phorbol esters and its impact on growth of human breast cancer cells.

C. Borner, D. Fabbro, S. Costa, 1986, Biochemical and biophysical research communications.

Effect of hypothyroidism and thyroid hormone replacement on the level of protein kinase C and protein kinase A in rat liver

D. Fabbro, B. Hemmings, C. Meier, 1991, FEBS letters.

In vitro cultures of epithelial cells from healthy breast tissues and cells from breast carcinomas.

D. Fabbro, T. Meyer, U. Regenass, 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

Doriano Fabbro, D. Fabbro, B. Monia, 1996, Nature Medicine.

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

Doriano Fabbro, D. Fabbro, J. Griffin, 2005, Blood.

Antisense- and antigene-based drug design strategies in oncology

D. Fabbro, K. Altmann, T. Geiger, 1998 .

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

Joanna L. Sharman, Adam J. Pawson, Helen E. Benson, 2015, Nucleic Acids Res..

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

J. Mestan, D. Fabbro, H. Lane, 2004, Cancer research.

Antisense oligonucleotides as inhibitors of signal transduction: development from research tools to therapeutic agents.

L. Miraglia, D. Fabbro, C. F. Bennett, 1996, Biochemical Society transactions.

bcl‐xl antisense treatment induces apoptosis in breast carcinoma cells

D. Fabbro, R. Stahel, U. Zangemeister‐Wittke, 2000, International journal of cancer.

Targeting cancer with small-molecular-weight kinase inhibitors.

D. Fabbro, G. Martiny-Baron, S. Cowan-Jacob, 2012, Methods in molecular biology.

Insulin-stimulated Protein Kinase B Phosphorylation on Ser-473 Is Independent of Its Activity and Occurs through a Staurosporine-insensitive Kinase*

M. Andjelkovic, D. Fabbro, B. Hemmings, 2001, The Journal of Biological Chemistry.

7.01 – Cancer Biology

D. Fabbro, C. García-echeverría, M. Pearson, 2007 .

SRC family kinases: potential targets for the treatment of human cancer and leukemia.

D. Fabbro, M. Warmuth, N. Gray, 2003, Current pharmaceutical design.

Trends in kinase drug discovery: targets, indications and inhibitor design

D. Fabbro, S. Knapp, H. Schiöth, 2021, Nature Reviews Drug Discovery.

The Binding Properties and Biological Activities of Bcl-2 and Bax in Cells Exposed to Apoptotic Stimuli*

C. Borner, D. Fabbro, U. Ravn, 1998, The Journal of Biological Chemistry.

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.

D. Fabbro, M. Warmuth, M. Hallek, 2003, Blood.

Protein Kinase C βII Specifically Binds to and Is Activated by F-actin*

D. Fabbro, Y. Hannun, G. Blobe, 1996, The Journal of Biological Chemistry.

Identification and characterization of NVP-BKM 120 , an orally available pan class I PI 3-Kinase inhibitor

W. Sellers, D. Fabbro, R. Schlegel, 2011 .

Overexpression of protein kinase C beta I in a murine keratinocyte cell line produces effects on cellular growth, morphology and differentiation.

T. Slaga, D. Fabbro, I. Weinstein, 1994, Cancer letters.

A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy.

D. Fabbro, R. Stahel, B. Baumann, 2000, Cancer research.

FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway.

D. Fabbro, Michael S. Cohen, J. Taunton, 2006, Cancer cell.

Expression and purification of human recombinant GST-FGF receptor-1.

D. Fabbro, G. Bold, S. Ferrari, 2001, Journal of biotechnology.

Lipids as Targets for Renal Cell Carcinoma Therapy

D. Fabbro, A. Huwiler, B. Stepanovska Tanturovska, 2023, International journal of molecular sciences.

Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin.

D. Fabbro, K. Kocher, D. Neuberg, 2004, The Journal of clinical investigation.

L 3 Differences in the kinase binding modes of imatinib , nilotinib and dasatinib are reflected in Abl transphosphorylation assays

D. Fabbro, S. Grzesiek, S. Cowan-Jacob, 2009 .

Differential Activation of the Phosphatidylinositol 3′-Kinase/Akt Survival Pathway by Ionizing Radiation in Tumor and Primary Endothelial Cells

D. Fabbro, O. Riesterer, M. Pruschy, 2004, Cancer Research.

A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.

D. Fabbro, P. Furet, C. García-echeverría, 2000, Journal of molecular biology.

A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and In vitro anti‐proliferative as well as In vivo anti‐tumor activity

D. Fabbro, T. Meyer, G. Caravatti, 1989, International journal of cancer.

Protein tyrosine kinase inhibitors: new treatment modalities?

D. Fabbro, D. Parkinson, A. Matter, 2002, Current opinion in pharmacology.

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRβ and FIP1L1-PDGFRα in vitro and in vivo

Sandra A. Moore, D. Fabbro, J. Griffin, 2005 .

The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.

Sandra A. Moore, D. Fabbro, J. Griffin, 2005, Blood.

RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR.

D. Fabbro, H. Lane, J. Fagin, 2008, Cancer research.

Phosphorylation, Signaling, and Cancer: Targets and Targeting

D. Fabbro, Y. Miyata, M. Pierobon, 2015, BioMed research international.

The Substrate-Activity-Screening methodology applied to receptor tyrosine kinases: a proof-of-concept study.

D. Fabbro, D. Seebach, H. Moebitz, 2012, European journal of medicinal chemistry.

Substrate profiling of IGF-1R and InsR: identification of a potent pentamer substrate.

D. Fabbro, D. Seebach, H. Moebitz, 2011, Bioorganic & medicinal chemistry letters.

Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.

Wolfgang Jahnke, Doriano Fabbro, Pascal Furet, 2010, Biochimica et biophysica acta.

Structural biology contributions to tyrosine kinase drug discovery.

D. Fabbro, S. Cowan-Jacob, H. Möbitz, 2009, Current opinion in cell biology.

PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.

D. Fabbro, D. Neuberg, J. Kutok, 2003, Cancer cell.

Effect of Potent and Selective Inhibitors of the Grb2 SH2 Domain on Cell Motility*

D. Fabbro, P. Furet, G. Caravatti, 1999, The Journal of Biological Chemistry.

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Donna Neuberg, Doriano Fabbro, Arghya Ray, 2005, Cancer cell.

Phenylamino‐Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC)

D. Fabbro, T. Meyer, N. Lydon, 1996, Archiv der Pharmazie.

Cyclic AMP-dependent protein kinase type I and type II and cyclic AMP binding in human mammary tumors.

D. Fabbro, U. Eppenberger, K. Biedermann, 1980, Advances in cyclic nucleotide research.

Targeting protein kinases in cancer therapy.

Doriano Fabbro, D. Fabbro, C. García-echeverría, 2002, Current opinion in drug discovery & development.

Phorbol ester inhibits erythropoietin production in human hepatoma cells (Hep G2).

D. Fabbro, P. Ratcliffe, K. Eckardt, 1992, The American journal of physiology.

Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.

D. Fabbro, J. Griffin, A. Kung, 2006, Gastroenterology.

Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).

D. Fabbro, P. Furet, J. Bain, 2003, The Biochemical journal.

The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.

Christine Stephan, Doriano Fabbro, Giorgio Caravatti, 2007, Cancer research.

Classical PKC isoforms in cancer.

D. Fabbro, G. Martiny-Baron, 2007, Pharmacological research.

Prediction of Resistance to Small Molecule FLT3 Inhibitors

Doriano Fabbro, Peter Marynen, Pascal Furet, 2004, Cancer Research.

Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia

Doriano Fabbro, Pascal Furet, D. Fabbro, 2006, Acta crystallographica. Section D, Biological crystallography.

Protein Tyrosine Kinases as Targets for Cancer and Other Indications

D. Fabbro, C. García-echeverría, M. Pearson, 2006 .

Targeted Therapy with Imatinib: An Exception or a Rule?

J. Mestan, D. Fabbro, P. Furet, 2005 .

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

Alasdair J. G. Gray, Joanna L. Sharman, Adam J. Pawson, 2017, Nucleic Acids Res..

The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients.

D. Fabbro, A. Harris, F. Caponigro, 1999, Cancer research.

Ribosomal protein S6 kinase and PKC in human mammary tumor cells.

D. Fabbro, T. Meyer, U. Eppenberger, 1989, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.

L. Miraglia, D. Fabbro, J. Giddings, 1996, Cancer research.

A public-private partnership to unlock the untargeted kinome.

Julian Blagg, Paul Workman, Bernhard Kuster, 2013, Nature chemical biology.

Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors.

D. Fabbro, C. Mol, D. Hosfield, 2004, Current opinion in drug discovery & development.

Estrogen stimulates growth of mammary tumor cells ZR-75 without activation of S6 kinase and S6 phosphorylation. Difference from epidermal growth factor and alpha-transforming growth-factor-induced proliferation.

D. Fabbro, U. Eppenberger, I. Novak‐Hofer, 1987, European journal of biochemistry.

Correlation between hormone dependency and the regulation of epidermal growth factor receptor by tumor promoters in human mammary carcinoma cells.

D. Fabbro, S. Costa, U. Eppenberger, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Zonal gene expression in human colon assessed by laser microdissection (LMD) and quantitative real-time RT-PCR

D. Fabbro, M. Stumm, C. Sieber, 2001 .

Characterization of kinase inhibitors using reverse phase protein arrays.

D. Fabbro, G. Martiny-Baron, D. Haasen, 2011, Methods in molecular biology.

AEE788

J. Mestan, D. Fabbro, H. Lane, 2004, Cancer Research.

Differential phosphoprofiles of EGF and EGFR kinase inhibitor-treated human tumor cells and mouse xenografts

M. Moran, Chris Orsi, D. Fabbro, 2004, Clinical Proteomics.

Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter.

D. Fabbro, I. Schieren, G. Duigou, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Expression of four protein kinase C isoforms in rat fibroblasts. Distinct subcellular distribution and regulation by calcium and phorbol esters.

C. Borner, D. Fabbro, I. Weinstein, 1992, The Journal of biological chemistry.

Different translocation of three distinct PKC isoforms with tumor-promoting phorbol ester in human platelets.

D. Fabbro, P. Erne, T. Woodtli, 1991, Biochemical and biophysical research communications.

Correction: Targeting Sphingosine Kinase 1 in Carcinoma Cells Decreases Proliferation and Survival by Compromising PKC Activity and Cytokinesis

D. Fabbro, A. Huwiler, N. Kotelevets, 2013, PLoS ONE.

Targeting Sphingosine Kinase 1 in Carcinoma Cells Decreases Proliferation and Survival by Compromising PKC Activity and Cytokinesis

D. Fabbro, A. Huwiler, N. Kotelevets, 2012, PloS one.

Inhibition of Protein Kinase c-Src Reduces the Incidence of Breast Cancer Metastases and Increases Survival in Mice: Implications for Therapy

D. Fabbro, A. Angelucci, M. Šuša, 2006, Journal of Pharmacology and Experimental Therapeutics.

Selective translocation of protein kinase C-delta in PC12 cells during nerve growth factor-induced neuritogenesis.

D. Fabbro, I. Weinstein, K. Teng, 1995, Molecular biology of the cell.

Immunological quantitation of phospholipid/CA2+‐dependent protein kinase of human mammary carcinoma cells: Inverse relationship to estrogen receptors

D. Fabbro, U. Eppenberger, Christoph J. Borner, 1987, International journal of cancer.

Pharmacological profile of the FLT3-Tyrosine Kinase Inhibitor AST487

D. Fabbro, J. Brueggen, G. Bold, 2005 .

Protein kinase C and mammary cell differentiation: involvement of protein kinase C alpha in the induction of beta-casein expression.

D. Fabbro, T. Meyer, N. Hynes, 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Feedback regulation of extracellular ATP-stimulated phosphoinositide hydrolysis by protein kinase C-alpha in bovine glomerular endothelial cells.

D. Fabbro, V. Briner, J. Pfeilschifter, 1997, Kidney international.

Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT

D. Fabbro, W. Pickl, F. Lee, 2007, Haematologica.

Upregulation of the S1P3 receptor in metastatic breast cancer cells increases migration and invasion by induction of PGE2 and EP2/EP4 activation.

D. Fabbro, J. Pfeilschifter, S. Schwalm, 2016, Biochimica et biophysica acta.

Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl–Pyrimidine Moiety

Ivan V. Buslov, D. Fabbro, M. Wymann, 2019, ACS medicinal chemistry letters.

The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors

Christopher Southan, Stephen PH Alexander, Eamonn Kelly, 2015, British journal of pharmacology.

Possible regulatory functions of protein kinase C-alpha and -epsilon isoenzymes in rat renal mesangial cells. Stimulation of prostaglandin synthesis and feedback inhibition of angiotensin II-stimulated phosphoinositide hydrolysis.

D. Fabbro, J. Pfeilschifter, A. Huwiler, 1991, The Biochemical journal.

Alpha-thrombin stimulates nuclear diglyceride levels and differential nuclear localization of protein kinase C isozymes in IIC9 cells.

D. Fabbro, K. Leach, M. Jarpe, 1992, The Journal of biological chemistry.

Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor.

P. Campochiaro, D. Fabbro, J. Wood, 1999, The American journal of pathology.

Inhibitory activity and selectivity of staurosporine derivatives towards protein kinase C

Doriano Fabbro, Andreas Fredenhagen, Giorgio Caravatti, 1994 .

Unphosphorylated α‐PKC exhibits phorbol ester binding but lacks protein kinase activity in vitro

D. Fabbro, I. Filipuzzi, R. Imber, 1993 .

Involvement of protein kinase C in the growth regulation of human breast cancer cells.

C. Borner, D. Fabbro, S. Costa, 1992, Cancer treatment and research.

EGF induces biphasic S6 kinase activation: Late phase is protein kinase C-dependent and contributes to mitogenicity

D. Fabbro, M. Šuša, G. Thomas, 1989, Cell.

4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders.

D. Fabbro, W. Löscher, M. Wymann, 2020, Journal of medicinal chemistry.

Extended kinase profiling of the Bcr-Abl inhibitor nilotinib

D. Fabbro, G. Martiny-Baron, T. Meyer, 2007 .

Growth-promoting effect of a protein-free hemodialysate used in situations of hypoxia and for tissue repair as measured via stimulation of S6-kinase.

D. Fabbro, W. Baschong, R. Imber, 1992, Arzneimittel-Forschung.

Protein kinase C in human renal cell carcinomas: role in invasion and differential isoenzyme expression

D. Fabbro, C. Gerharz, H. Gabbert, 2000, British Journal of Cancer.

Activation of protein kinase C subtypes alpha, gamma, delta, epsilon, zeta, and eta by tumor-promoting and nontumor-promoting agents.

D. Fabbro, T. Meyer, J. Pfeilschifter, 1997, Biochemical pharmacology.

Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate.

D. Fabbro, N. Gray, 2014, Methods in enzymology.

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Catalytic receptors

Christopher Southan, Stephen PH Alexander, Eamonn Kelly, 2017, British journal of pharmacology.

Acylated-acyl carrier protein stabilizes the Pseudomonas aeruginosa WaaP lipopolysaccharide heptose kinase

D. Fabbro, E. Fang, R. Chopra, 2018, Scientific Reports.

The Phosphodiesterase Inhibitor SQ 20006 Selectively Blocks Mitogen Activation of p70S6k and Transition to S Phase of the Cell Division Cycle without Affecting the Steady State Phosphorylation of eIF-4E (*)

D. Fabbro, T. Meyer, S. Morley, 1995, The Journal of Biological Chemistry.

Homogeneous purification of human recombinant GST-Akt/PKB from Sf9 cells.

D. Fabbro, T. Roberts, S. Ferrari, 1999, Protein expression and purification.

Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders.

D. Fabbro, M. Zvelebil, W. Löscher, 2018, Journal of medicinal chemistry.

Protein kinase C down-regulation enhances cAMP-mediated induction of urokinase-type plasminogen activator mRNA in LLC-PK1 cells.

D. Fabbro, Y. Nagamine, A. Ziegler, 1991, The Journal of biological chemistry.

Expression and partial characterization of rat protein kinase C-delta and protein kinase C-zeta in insect cells using recombinant baculovirus.

D. Fabbro, T. Meyer, N. Lydon, 1992, Journal of cellular biochemistry.

FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model

D. Fabbro, J. Griffin, D. Gilliland, 2005, Oncogene.

Chemical genetic approach identifies microtubule affinity‐regulating kinase 1 as a leucine‐rich repeat kinase 2 substrate

A. Bauer, T. Bouwmeester, D. Fabbro, 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD

D. Fabbro, O. Riess, M. Wymann, 2020, Neuropharmacology.

THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets

Arthur Christopoulos, Christopher Southan, Jörg Striessnig, 2019, British journal of pharmacology.

Tracing pathway activities with kinase inhibitors and reverse phase protein arrays

Doriano Fabbro, Markus Ehrat, Hans Voshol, 2009, Proteomics. Clinical applications.

Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors.

Doriano Fabbro, Nathanael Gray, D. Fabbro, 2003, Current medicinal chemistry. Anti-cancer agents.

( S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase.

D. Fabbro, J. Burke, M. Wymann, 2019, Journal of medicinal chemistry.

Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models

G. Reifenberger, D. Fabbro, M. Weller, 2020, Journal of neurochemistry.

Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities.

D. Fabbro, B. Schäfer, H. Troxler, 2008, Cancer research.

Regulation of protein kinase C isozymes in kidney regeneration.

D. Fabbro, L. Dong, J. Stevens, 1993, Cancer research.

Hypoxia-induced accumulation of erythropoietin mRNA in isolated hepatocytes is inhibited by protein kinase C

D. Fabbro, K. Eckardt, A. Kurtz, 2004, Pflügers Archiv.

Nilotinib, in Comparison to Both Dasatinib and Imatinib, Possesses a Greatly Prolonged Residence Time When Bound to the BCR-ABL Kinase SH1 Domain

D. Fabbro, W. Jahnke, S. Cowan-Jacob, 2011 .

Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.

D. Fabbro, C. Bailly, M. Sancelme, 1997, Journal of medicinal chemistry.

High-Resolution Seminal Plasma Protein Patterns in Normal and Infertile Men

D. Fabbro, A. Campana, U. Eppenberger, 1982 .

Protein kinase C isozyme expression and down-modulation in growing, quiescent, and transformed renal proximal tubule epithelial cells.

D. Fabbro, L. Dong, J. Stevens, 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Corrigendum to “Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation” [Bioorg. Med. Chem. Lett. 23 (2013) 3741–3748]

D. Fabbro, J. Hamon, P. Furet, 2013 .

Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo[2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1/2 pathway.

D. Fabbro, M. Šuša, A. Teti, 2004, Bone.

Biological Crystallography Structural Biology Contributions to the Discovery of Drugs to Treat Chronic Myelogenous Leukaemia

D. Fabbro, G. Rummel, P. Furet, 2022 .

Immunocharacterization of protein kinase C isoenzymes in rat kidney glomeruli, and cultured glomerular epithelial and mesangial cells.

D. Fabbro, J. Pfeilschifter, A. Huwiler, 1993, Experimental nephrology.

Altered protein kinase C in a mast cell variant defective in exocytosis.

C. Borner, D. Fabbro, P. Erne, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Unphosphorylated alpha-PKC exhibits phorbol ester binding but lacks protein kinase activity in vitro.

D. Fabbro, I. Filipuzzi, R. Imber, 1993, Journal of cellular biochemistry.

The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors

Adam J Pawson, Stephen P. H. Alexander, C. Southan, 2015, British journal of pharmacology.

Protein Kinase C (cid:98) II Specifically Binds to and Is Activated by F-actin*

D. Fabbro, Y. Hannun, G. Blobe, 2022 .

Inhibitors of Protein Kinases and Protein Phosphates Contributors

L. Meijer, D. Fabbro, M. Yacoub, 2005 .

The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax

D. Fabbro, L. Cascione, A. Stathis, 2019, Cancers.

Abstract 671: BKM120-mediated G2 arrest: Structural and functional segregation of off-target action and PI3K inhibition

D. Fabbro, M. Zvelebil, Roger L. Williams, 2015 .

Notch Inhibition in Cancer: Challenges and Opportunities.

D. Fabbro, M. Murone, R. Lehal, 2020, Chimia.

An ELISA for PDGFR phosphorylation: Comparison of effects of STI571 on cellular Bcr-Abl, c-Kit and PDGFR-β protein kinases

D. Fabbro, T. Meyer, P. Manley, 2004 .

25 Years of Small Molecular Weight Kinase Inhibitors: Potentials and Limitations

D. Fabbro, 2015, Molecular Pharmacology.

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Other ion channels

Christopher Southan, Stephen PH Alexander, Eamonn Kelly, 2017, British journal of pharmacology.

Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.

J. Mestan, D. Fabbro, W. Jahnke, 2010, Biochimica et biophysica acta.

PKC412 Inhibits In Vitro Growth of Neoplastic Mast Cells Expressing the D816V-Mutated Variant of KIT: Comparison with AMN107 and Imatinib, and Evaluation of Drug-Interactions.

D. Fabbro, S. Derdak, W. Pickl, 2005 .

International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands

J. Changeux, R. Neubig, C. Langmead, 2014, Pharmacological Reviews.

The ceramide kinase inhibitor NVP‐231 inhibits breast and lung cancer cell proliferation by inducing M phase arrest and subsequent cell death

D. Fabbro, J. Pfeilschifter, S. Schwalm, 2014, British journal of pharmacology.

Targeting protein kinases in cancer therapy: a success?

D. Fabbro, M. Pearson, 2004, Expert review of anticancer therapy.

7.01 – Cancer Biology

D. Fabbro, C. García-echeverría, M. Pearson, 2007 .

Therapeutically targeted anticancer agents: inhibitors of receptor tyrosine kinases.

D. Fabbro, C. García-echeverría, 2004, Mini-Reviews in Medical Chemistry.